Development Of Improved Chromatographic Methods For The Separation Of Synthetic Peptides Medications And Associated Impurities

By Paul Rainville, Brianna Clements, Adam Bengtson, and Norris Wong, Waters Corporation

Glucagon-Like Peptide-1 agonists (GLP-1s) are a class of synthetic peptide medications widely prescribed for managing obesity and type-II diabetes. Recently, drugs like semaglutide have gained significant attention as effective weight management treatments, following promising results in clinical trials. As the use of GLP-1s becomes increasingly prevalent, ensuring robust quality control through versatile, sensitive, and reproducible chromatography methods is essential. Although chromatographic techniques exist for some commonly used GLP-1s, there is currently no single method available to separate an updated panel of these synthetic peptides. Moreover, the U.S. Food and Drug Administration (FDA) has recently issued Product Specific Guidelines (PSGs) for several synthetic peptides, emphasizing the critical need for thorough impurity analysis.

To advance pharmaceutical quality and patient safety, we invite researchers, analysts, and industry professionals to explore and contribute to the development of comprehensive chromatographic methods for GLP-1s. Access the full poster to learn more.